国产精品ⅴ无码大片在线看,激情影院内射美女,动物与人性生活一区二区三区性生活激情视频,久久久久免费毛a片免费一瓶梅

    尊龍凱時·(中國區)人生就是搏!

    EN
    ×
    EN

    • 業務咨詢

      中國：

      Email: marketing@www.msjidi.com

      業務咨詢專線：400-780-8018

      （僅限服務咨詢，其他事宜請撥打川沙總部電話）

      川沙總部電話: +86 (21) 5859-1500

      海外：

      +1(781)535-1428(U.S.)

      0044 7790 816 954 (Europe)

      Email:marketing@medicilon.com
    在線留言×

    搜索結果包含 Pharmacokinetic 的內容

    Jul 11,2025
    端錨聚合酶抑制劑G007-LK具有治療結直腸癌的潛力，本研究中PK實驗通過尊龍凱時進行
    Medicilon Preclinical Research LCC performed the pharmacokinetic studies.
    查看更多
    Jul 10,2025
    JX01是一種抗心力衰竭候選藥物，具有良好的PK特性和安全性。PK實驗通過尊龍凱時進行
    Pharmacokinetic studies were commissioned by Medicilon.
    查看更多
    Jul 10,2025
    四價廣譜中和雙特異性抗體ISH0339的臨床前評估通過尊龍凱時進行
    An indirect antigen ELISA assay was used for the detection of ISH0339 in rat serum (Medicilon). tbad003.pngPharmacokinetic analysis of single-dose ISH0339 administration was conducted by. Extended toxicity study of single-dose ISH0339 was conducted by M
    查看更多
    Jul 02,2025
    靶向HGF的人源化中和抗體的臨床前開發，本研究中PK/TK及ADA通過尊龍凱時進行
    Pharmacokinetics, toxicokinetics and anti-drug antibodies of YYB-101 in cynomolgus monkeys were conducted by the Test and Control Article Department of Medicilon Preclinical Research, LLC, in accordance with regulations outlined in the USDA Animal Welfare
    查看更多
    Jul 02,2025
    ASCT1/2抑制劑可用于治療精神分裂癥和視覺障礙，本研究中小鼠PK實驗通過尊龍凱時進行
    Pharmacokinetic studies in mice for L-4FPG, L-4OHPG, and L-4ClPG were performed by Medicilon.
    查看更多
    Jun 12,2025
    雙靶向HDAC抑制劑和ATM激活劑SP-1-303抑制雌激素受體陽性乳腺癌細胞生長，本研究中PK實驗通過尊龍凱時進行
    Pharmacokinetic studies performed by Medicilon.
    查看更多
    Jun 11,2025
    第二代前列腺素受體拮抗劑，本研究中眼部PK實驗通過尊龍凱時進行
    Ocular Pharmacokinetic studies were performed at Medicilon.
    查看更多
    Jun 11,2025
    SIRT6變構激活劑在結直腸癌中發揮治療作用，本研究中PK實驗通過尊龍凱時進行
    Pharmacokinetic studies were performed by Shanghai Medicilon Inc, China, following standard protocols.
    查看更多
    Jul 06,2023
    發現新型RAGE/SERT雙重抑制劑，可用于治療阿爾茨海默病和抑郁癥。其中藥代動力學研究是通過委托尊龍凱時進行
    Alzheimer's disease (AD) is a progressive and devastating neurodegenerative disorder, characterized by the presence of β-amyloid (Aβ) peptide plaques, neurofibrillary tangles, and neuroinflammatio
    查看更多
    Jul 06,2023
    IAP蛋白是有吸引力的癌癥治療靶點。SM-406 是一種口服有效的IAP拮抗劑。SM-406 在雄性SD大鼠、比格犬和NHP中的PK研究通過尊龍凱時進行
    Apoptosis is a cellular process critical to the normal development and homeostasis of multicellular organisms.?The inhibitor of apoptosis proteins (IAPs) are a class of key apoptosis regulators.
    查看更多
    Jul 06,2023
    設計合成一系列用于治療胃癌的多靶點受體酪氨酸激酶抑制劑，并進行生物學評價。其中藥代動力學分析通過尊龍凱時進行
    Gastric cancer is the second most lethal cancer across the world. Compounds 8f, inhibits FGFR1 signaling pathways as well as induces cell apoptosis, is a potential agent for the treatment of gastric c
    查看更多
    Jul 06,2023
    FBPase是與腫瘤和2型糖尿病相關的一個有前景的靶點。化合物W8對FBPase表現出高選擇性。W8的藥代動力學研究通過尊龍凱時進行
    Fructose-1,6-bisphosphatase (FBPase) is a promising target associated with cancer and type 2 diabetes. Compounds W8 and W8k exhibit high selectivity against FBPase and W8 effectively reduces blood glu
    查看更多
    Jul 06,2023
    藥物發現中的挑戰之一是識別高質量的先導化合物。此研究中PK結果表明L12可作為針對PDE5的先導化合物，進一步研究和開發。L12的PK分析通過尊龍凱時進行
    Scaffold hopping refers to computer-aided screening for active compounds with different structures against the same receptor to enrich privileged scaffolds, which is a topic of high interest in organi
    查看更多
    Jul 06,2023
    ANO1是一個潛在的鎮痛靶點。DFBTA是一種有效的ANO1抑制劑，具有優異的藥代動力學特性。體內PK測試通過尊龍凱時進行
    Current pain management is largely limited to opioids and non-steroidal anti-inflammatory drugs. Developing new analgesic drugs remains important to address the unmet medical needs of chronic pain pat
    查看更多
    Jul 06,2023
    開發和驗證大鼠血漿中Nobiliside A定量的LC/MS/MS方法
    Nobiliside A, a new triterpene glycoside, exhibits some biological activities including antifungal and cytotoxic effects. A LC/MS/MS method was developed and validated for determination of Nobiliside
    查看更多
    Jul 06,2023
    PTX-HSN是一種高效納米系統，具有較高耐受劑量，可將PTX遞送至卵巢癌并增強主動腫瘤靶向性。此研究中所有體內實驗均通過尊龍凱時進行
    Paclitaxel-loaded hyaluronan solid nanoemulsions (PTX-HSNs) were successfully fabricated for the delivery of PTX to improve ovarian cancer treatment via active tumor targeting. The in vivo #toxicity,
    查看更多
    Jul 06,2023
    開發一種簡單準確的液相色譜串聯質譜法，用于大鼠血漿中牡荊素鼠李糖苷的測定和體內PK研究。此研究中動物研究通過尊龍凱時進行
    A simple and accurate liquid chromatography coupled with tandem mass spectrometry method was developed for determination and in vivo pharmacokinetic studies of vitexin rhamnoside in rat plasma. Practi
    查看更多
    Jul 06,2023
    AD80是一種多激酶抑制劑，在多種肝細胞癌臨床前動物模型中具有抗腫瘤活性，AD80在血漿中的含量通過尊龍凱時進行LC-MS/MS測定
    Liver cancer is the fourth greatest cause of cancer related mortality. AD80 is a multi-kinase inhibitor with anti-tumoral activity across a variety of hepatocellular carcinoma (HCC) preclinical models
    查看更多
    Jul 06,2023
    以PROTAC為代表的靶向蛋白質降解是藥物發現的新興策略，研究人員設計并合成了多種PROTAC，此研究中所有PK研究均通過尊龍凱時進行
    Targeted protein degradation (TPD) exemplified by PROTACs is an emerging strategy for next generation drug discovery. Threonine tyrosine kinase (TTK) is a dual-specific protein kinase that catalyzes p
    查看更多
    Jul 06,2023
    BRD4抑制劑可用于治療腎纖維化，ZLD2218可有效抑制BRD4活性，對ZLD2218的PK研究通過尊龍凱時進行
    Uncovering new therapeutics for kidney fibrosis hold promise for chronic kidney disease (CKD). BRD4 inhibition ameliorated kidney injury and fibrosis. ZLD2218 exhibited the potent inhibitory activity
    查看更多

    川沙總部

    地址: 上海市浦東新區川大路585號

    郵編: 201299

    電話: +86 (21) 5859-1500（總機）

    傳真: +86 (21) 5859-6369

    業務咨詢

    中國：

    Email: marketing@medicilon.com

    業務咨詢專線：400-780-8018

    （僅限服務咨詢，其他事宜請撥打川沙
    總部電話）

     

    海外：

    Email:?marketing@medicilon.com

    Tel: +1 (617) 888-9294(U.S.)

    Tel: 0044 7790 816 954 (Europe)

    Tel: +82 70-8269-5849 (Korea)

    Tel: +81 80-4421-6898 (Japan)

    ? 2022 上海尊龍凱時生物醫藥股份有限公司 保留所有權利 滬ICP備10216606號-3
    滬公網安備 31011502012909號|網站地圖|技術支持：集錦科技
    安全性評價 溶瘤病毒 PDX模型 IND申報 AAALAC
    ×
    搜索驗證